Clinical trials: multiple sclerosis
Multiple Sclerosis
Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple Sclerosis
The primary objective of this study is to establish scores of Cognitive impairment (CI) of the 3 DigiCog [Brief Computerized Cognitive Assessment for Multiple Sclerosis (BCCAMS) app] tests [Computerized Speed Cognitive Test…
- Trial name
- DigiToms (NCT04756700)
- Testing
- DigiCog (BCCAMS app), Konectom Application
- Where
- France
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Biogen
Multiple Sclerosis
12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.
The Electronic Device - The RebiSmart™ is an electronic injection device that is being studied for the delivery of Merck Serono's Rebif® New Formulation.
- Trial name
- NCT00735007
- Testing
- Rebif® New Formulation (RNF) using RebiSmartTM
- Where
- 6 sites in United States, Canada and 4 more
- Volunteers
- 106 people
- Sponsor
- EMD Serono
Multiple Sclerosis, Relapsing-Remitting
A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)
The purpose of this study is to collect real-world data and to gain insights about long-term usage of ozanimod (Zeposia ®), its effect on well-defined outcome parameters comprising participant-relevant outcomes, as well as…
- Trial name
- OzEAN (NCT05335031)
- Testing
- Ozanimod
- Where
- Germany
- Volunteers
- 450 people
- Sponsor
- Bristol-Myers Squibb
Multiple Sclerosis (MS)
MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study
The primary objective of this sub-study is to supplement the Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) dataset with coronavirus disease 2019 (COVID-19)-related health information obtained…
- Trial name
- NCT05058729
- Where
- 6 sites in United States
- Volunteers
- 1,507 people
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. Other goals of the study are to determine if, over time, BG00012 treatment can decrease the number of certain types of…
- Trial name
- CONFIRM (NCT00451451)
- Testing
- BG00012, Glatiramer Acetate
- Where
- 195 sites in United States, Belarus and 26 more
- Volunteers
- 1,417 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
Adherence Trial With MS LifeLines ® Services
This is a Phase IV study to compare the current level of MS LifeLines ® (MSLL) services (face-to-face nursing visits and phone contacts) with customized MSLL services, to determine the optimal services to enhance medication…
- Trial name
- NCT01905527
- Testing
- Standard Services of Group A (Group A1), Customized Services of Group A (Group A2), Group B
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- EMD Serono
Multiple Sclerosis, Relapsing-Remitting
A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
The primary objective of this study is to evaluate the radiological efficacy of SC natalizumab over time through Week 24 in natalizumab-naïve participants, as measured by brain magnetic resonance imaging (MRI).
- Trial name
- NCT05532163
- Testing
- Natalizumab
- Where
- 2 sites in Germany
- Volunteers
- 1 people
- Sponsor
- Biogen
Scleroderma, Systemic, Digital Ulcer
Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis
This study is performed to consider the safety and healing ability of diosmin in patients with systemic sclerosis (scleroderma) and open sores on their fingers (digital ulcers).
- Trial name
- NCT06256575
- Testing
- Diosmin
- Where
- 5 sites in Canada
- Volunteers
- 45 people
- Sponsor
- Primus Pharmaceuticals
Amyotrophic Lateral Sclerosis
A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALS
This is an open-label, follow-on phase 1 study to assess the long-term safety and tolerability of continuous i.c.v administration of 4 μg sNN0029/day in patients with ALS who previously participated in study sNN0029-003
- Trial name
- NCT02269436
- Testing
- sNN0029 infusion solution
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 11 people
- Sponsor
- Newron Sweden AB
Relapsing-Remitting Multiple Sclerosis (RRMS)
Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
The primary objective of the study is to evaluate the effects of treatment with daclizumab on the proportion of participants relapse-free at 6 months in Relapsing-Remitting Multiple Sclerosis (RRMS) participants, who switched…
- Trial name
- SUSTAIN (NCT02881567)
- Testing
- Daclizumab
- Where
- 11 sites in United States, Canada and 3 more
- Volunteers
- 41 people
- Sponsor
- Biogen
Multiple Sclerosis
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial
The purpose of the study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months in patients who previously participated in the MS-F204 study or until it becomes…
- Trial name
- NCT00649792
- Testing
- Fampridine-SR
- Where
- 42 sites in United States, Canada
- Volunteers
- 214 people
- Sponsor
- Acorda Therapeutics
Relapsing-Remitting Multiple Sclerosis
A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
The purpose of this study is to determine if medication designed to improve memory will help patients with Multiple Sclerosis (MS) who are experiencing memory problems using fMRI to track brain activity.
- Trial name
- NCT00315367
- Testing
- Donepezil HCI (drug)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Neurognostics
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the safety, tolerability and activity of ibudilast administered twice daily over a 96 week period in subjects with…
- Trial name
- NCT01982942
- Testing
- ibudilast
- Where
- 28 sites in United States
- Volunteers
- 255 people
- Sponsor
- MediciNova
Multiple Sclerosis, Relapsing-Remitting
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
This study will evaluate the efficacy and safety of ocrelizumab in participants with RRMS who have had a suboptimal response to an adequate course of DMT.
- Trial name
- NCT02637856
- Testing
- Ocrelizumab
- Where
- 82 sites in United States, Canada
- Volunteers
- 608 people
- Sponsor
- Genentech, Inc.
Systemic Sclerosis
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis
The main purpose of the study is to see if GLPG1690 helps (together with the standard of care treatment) in the treatment of the skin and other areas affected by systemic sclerosis.
- Trial name
- NOVESA (NCT03798366)
- Testing
- GLPG1690
- Where
- 18 sites in United States, Belgium and 4 more
- Volunteers
- 33 people
- Sponsor
- Lakefront Biotherapeutics NV
Multiple Sclerosis
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
The primary objective of the study is to evaluate the efficacy of BIIB033 in participants with active relapsing multiple sclerosis (MS) when used concurrently with Avonex.
- Trial name
- SYNERGY (NCT01864148)
- Testing
- BIIB033, Avonex
- Where
- 72 sites in United States, Canada and 10 more
- Volunteers
- 419 people
- Sponsor
- Biogen
Renal Angiomyolipoma
A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)
The purpose of this prospective study is to assess the safety and efficacy of everolimus in Taiwanese patients with renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) .
- Trial name
- NCT05252585
- Testing
- Everolimus
- Where
- 4 sites in Taiwan
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Evaluating the Effects of the EXOPULSE Suit on Mobility, Walking Ability, and Balance in People With Multiple Sclerosis
This clinical research study is investigating whether the EXOPULSE Suit, a wearable device that delivers electrical stimulation, can help improve movement difficulties caused by spasticity in adults with multiple sclerosis (MS).
- Trial name
- EXO-MS (NCT07897760)
- Testing
- Electrostimulation suit
- Where
- 2 sites in United States, Germany
- Volunteers
- 100 people
- Sponsor
- Otto Bock Healthcare Products GmbH
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the recommended Part 2 dose (RP2D) of ATA188 as monotherapy in Part 1, and to evaluate the effect of…
- Trial name
- EMBOLD (NCT03283826)
- Testing
- ATA188
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 134 people
- Sponsor
- Atara Biotherapeutics
Autoimmune Diseases, Multiple Sclerosis
First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641
A Phase I First-in-Human, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate Safety, Tolerability, and Pharmacokinetics after Single and Multiple Oral Dose of LPX-TI641.
- Trial name
- NCT05853835
- Testing
- LPX-TI641
- Where
- 2 sites in United States, Jordan
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- LAPIX Therapeutics Inc.